Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. monthly Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E17.74 EPS (ttm)2.40 Insider Own0.10% Shs Outstand5.88B Perf Week-0.82%
Market Cap249.86B Forward P/E13.82 EPS next Y3.08 Insider Trans-4.76% Shs Float5.80B Perf Month0.31%
Income14.41B PEG2.38 EPS next Q0.64 Inst Own74.20% Short Float0.86% Perf Quarter-4.58%
Sales53.37B P/S4.68 EPS this Y68.20% Inst Trans0.01% Short Ratio1.94 Perf Half Y13.84%
Book/sh12.14 P/B3.50 EPS next Y2.53% ROA14.20% Target Price45.35 Perf Year14.98%
Cash/sh2.93 P/C14.49 EPS next 5Y7.45% ROE33.70% 52W Range33.20 - 46.47 Perf YTD-2.57%
Dividend1.44 P/FCF25.54 EPS past 5Y10.40% ROI11.00% 52W High-8.48% Beta0.81
Dividend %3.39% Quick Ratio1.20 Sales past 5Y-0.80% Gross Margin79.10% 52W Low28.10% ATR0.97
Employees90200 Current Ratio1.40 Sales Q/Q1.00% Oper. Margin26.40% RSI (14)47.83 Volatility1.65% 2.33%
OptionableYes Debt/Eq0.58 EPS Q/Q45.80% Profit Margin44.60% Rel Volume1.44 Prev Close42.53
ShortableYes LT Debt/Eq0.47 EarningsJan 29 BMO Payout33.40% Avg Volume25.64M Price42.53
Recom2.60 SMA20-0.14% SMA50-2.05% SMA2005.44% Volume0 Change0.00%
Dec-11-18Downgrade JP Morgan Overweight → Neutral
Nov-01-18Downgrade BMO Capital Markets Outperform → Market Perform
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Jan-22-19 06:06AM  Better Buy: Pfizer vs. AbbVie Motley Fool
Jan-21-19 03:24PM  The Dogs of the Dow 2019: 10 Dividend Stocks to Watch Kiplinger
10:15AM  3 Stocks That Are Easy to Understand Motley Fool
07:35AM  The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips Zacks
03:12AM  GSK Chairman Hampton to step down ahead of split Reuters
01:01AM  [$$] GSK chairman to step down ahead of break-up Financial Times
Jan-20-19 09:15AM  Would Pfizer Shareholders Win With an Acquisition of Amarin? Motley Fool
08:59AM  Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes? Motley Fool
Jan-18-19 02:15PM  Top Stock Reports for Pfizer, Biogen & Schwab Zacks
12:36PM  Bulls bet on this biopharma company. Plus, the update on ... CNBC Videos
09:11AM  Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY Zacks
08:36AM  Dow 30 Stock Roundup: JPM & AXP Earnings Disappoint, GS & UNH Impress Zacks
08:02AM  Baxter (BAX) Gains From Sharesource's Global Success Rates Zacks
Jan-17-19 03:36PM  The Stable Value Stock Is Built to Weather Market Storms GuruFocus.com
09:06AM  J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect Zacks
08:12AM  3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group InvestorPlace
Jan-16-19 03:30PM  Court rules against Pfizer in religious discrimination suit Associated Press
08:11AM  Is Pfizer a Buy? Motley Fool
07:35AM  Fiserv to buy First Data in $22B all-stock deal CNBC Videos
Jan-15-19 05:45PM  Pfizer (PFE) Gains But Lags Market: What You Should Know Zacks
09:40AM  Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer Zacks
08:00AM  Pfizer Gets FDA's Priority Review for Rare Disease Candidate Zacks
Jan-14-19 08:04PM  Here's How Pfizer Gained 20.5% in 2018 Motley Fool
06:00PM  Democrats target drug prices CNBC Videos
05:52PM  Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe Investor's Business Daily
05:24PM  Stocks slip as corporate earnings season begins Yahoo Finance Video
04:23PM  This Biotech Stock Plunged On Its Looming Rivalry With Pfizer Investor's Business Daily
12:42PM  House Dems announce sweeping investigation of drug pricing Associated Press
12:09PM  House Democrats launch drug-pricing probe into a dozen major health-care companies CNBC
11:57AM  Sell Amarin Stock on the Recent Takeover Rumors Rally InvestorPlace
11:29AM  How To Approach Q4 Earnings: The Global Perspective Benzinga
10:50AM  Modern Value Investing: Adding to the Value Investing Toolbox GuruFocus.com
08:56AM  Pfizer's new drug applications for tafamidis accepted for filing by FDA MarketWatch
08:00AM  US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy Business Wire
Jan-13-19 08:45PM  Here Are the 2019 Dogs of the Dow Motley Fool
Jan-12-19 12:00PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-11-19 06:11PM  NASH Space in Focus in 2019 as Firms Look to Diversify Zacks
03:06PM  7 Pharmaceutical Stocks That Just Raised Prices This Year InvestorPlace
09:56AM  Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer Zacks
09:45AM  Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet Zacks
09:25AM  Pfizer and the Urge to Merge TheStreet.com
09:16AM  For Esperion Therapeutics, 2019 Could Be a Big Year Motley Fool
07:44AM  This Market May Just Be in an Uptrend: Market Recon TheStreet.com
06:22AM  4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 Zacks
06:00AM  For Strong Returns, Try Stock in Top Spenders on R&D Barrons.com
Jan-10-19 04:13PM  Will Pfizer Join The Buying Spree With This Small Biotech Stock? Investor's Business Daily
03:19PM  Athenex Completes Enrollment Target for Breast Cancer Study Zacks
02:49PM  3 Defensive ETFs to Protect Yourself From Another Market Selloff InvestorPlace
01:15PM  Amarin Corporation's Stock Heats Up on Buyout Chatter Motley Fool
09:56AM  Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting Zacks
Jan-09-19 10:20PM  Morning News Call - India, January 10 Reuters
06:45PM  Pfizer to shut two manufacturing plants in India Reuters
01:29PM  JP Morgan's Dimon hosted a private dinner for pharma executives, and a major topic was Amazon CNBC
09:28AM  Cell therapy pioneer eyes Bay Area manufacturing American City Business Journals
06:36AM  3 Reasons Buying Celgene Right Now Makes Sense Motley Fool
Jan-08-19 08:00AM  Dogs of the Dow Win in 2018: Will ETFs See Success in 2019? Zacks
07:15AM  3 Companies You Don't Realize You Rely On Every Day Motley Fool
Jan-07-19 10:00PM  3 Things Pfizer's New CEO Just Said That Investors Will be Glad to Hear Motley Fool
08:44PM  Gilead, Pfizer Execs Suggest Even More Pharma M&A Is on Way Bloomberg
06:16PM  Top Dow Stocks for 2018 Investopedia
05:45PM  Pfizer (PFE) Gains But Lags Market: What You Should Know Zacks
04:57PM  Aerie's Rhopressa Succeeds in Study on Japanese Patients Zacks
04:09PM  Why Exact Sciences Soared Today Motley Fool
03:51PM  Biogen Inks Two Deals to Make Drugs for Neurological Diseases Zacks
01:05PM  GlaxoSmithKline CEO Emma Walmsley gets 'radical' about reshaping portfolio CNBC
11:47AM  GSK CEO: Pfizer venture creates value for both our consum... CNBC Videos
10:56AM  As Patent Expirations Loom, the Clock Is Ticking on AbbVie Stock InvestorPlace
09:30AM  Company News For Jan 7, 2019 Zacks
09:27AM  Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks
09:18AM  J.P. Morgan Healthcare Conference kicks off Monday with focus on Trump, Amazon CNBC
04:00AM  The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie Zacks
Jan-04-19 04:24PM  Bristol To Become Top 5 Pharma And Other Fallout From Celgene Takeover Investor's Business Daily
10:07AM  Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate Zacks
08:06AM  Pfizer Rises 3% Investing.com
07:29AM  Pfizer Begins Pivotal Study on Alopecia Areata Candidate Zacks
06:50AM  Today's Research Reports on Trending Tickers: Pfizer and Bristol-Myers Squibb ACCESSWIRE
Jan-03-19 01:24PM  Why Johnson & Johnson Stock is Clearly Set to Rise Again InvestorPlace
12:35PM  3 Biopharma Stocks to Buy for Their Robust Dividend Yields InvestorPlace
10:12AM  Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019? Zacks
08:30AM  Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata Business Wire
Jan-02-19 01:01PM  The best-performing sector last year could be the top bet for 2019, technician says CNBC
10:00AM  Your first trade for Wednesday, January 2 CNBC
09:36AM  Final Trades: FDX, PFE and more CNBC Videos
09:32AM  The 3 Best Stocks in the Dow Jones in 2018 Motley Fool
09:25AM  Pfizer Could Be a Healthy Option in This Volatile Market TheStreet.com
08:07AM  This 2019 Market Optimism Is Misplaced: Market Recon TheStreet.com
07:28AM  Dow Jones Futures Signal Sell-Off To Open 2019 Stock Market; Trump Says 'Let's Make A Deal' Investor's Business Daily
Jan-01-19 09:13PM  Drugmakers Raise Prices on Hundreds of Medicines The Wall Street Journal
08:33PM  [$$] Drugmakers Raise Prices on Hundreds of Medicines The Wall Street Journal
07:58PM  [$$] Drugmakers Raise Prices on Hundreds of Medicines The Wall Street Journal
11:11AM  3 Stocks to Build Your Portfolio Around Motley Fool
Dec-31-18 04:25PM  This Is The Top Dow Stock Of 2018 And It's Not Even Close Investor's Business Daily
04:15PM  Does Pfizer Have A Multibillion-Dollar Replacement For Opioids? Investor's Business Daily
04:05PM  Stocks Today Brush Off The Bears; Will These 4 Lead The Dow Jones In 2019? Investor's Business Daily
10:00AM  Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire
05:30AM  Pfizer Stock Withstood a Health Care Sector Stumble to Be a 2018 Winner Barrons.com
Dec-28-18 05:45PM  Pfizer (PFE) Gains As Market Dips: What You Should Know Zacks
05:40PM  Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan Zacks
09:46AM  Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019? Zacks
Dec-27-18 10:00AM  Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immunicum AB (publ); Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Leap Therapeutics, Inc.; Nektar Therapeutics; Zenith Epigenetics Ltd., and Kineta Immuno-Oncology, LLC, as well as development agreement with Antares Pharma, Inc. It also has a collaboration agreement with Aileron Therapeutics, Inc. The company was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
READ IAN CChairman & CEONov 02Option Exercise26.641,100,20129,312,5881,760,958Nov 06 03:46 PM
PFIZER INC10% OwnerOct 15Buy18.0055,5561,000,00822,032,040Oct 17 05:17 PM
Dolsten MikaelPresident R&DSep 13Option Exercise24.56181,7124,462,167234,299Sep 17 04:08 PM
OLSON LAURIE JExecutive Vice PresidentAug 13Sale41.0010,214418,77472,672Aug 14 05:04 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 03Sale39.5125,6421,013,171102,412Aug 06 03:19 PM
GOETTLER MICHAELGroup PresidentAug 01Sale39.7019,198762,11611,924Aug 03 03:38 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerAug 01Sale40.1626,8141,076,93383,846Aug 03 03:36 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentAug 01Sale40.0420,942838,5724,643Aug 03 03:35 PM
DAMELIO FRANK AExecutive Vice PresidentAug 01Sale40.00150,4846,019,360337,391Aug 03 03:33 PM
SUSMAN SALLYExecutive Vice PresidentJul 20Sale37.2240,3811,502,925115,096Jul 24 01:09 PM
READ IAN CChairman & CEOJul 16Sale37.36486,75318,186,315659,440Jul 17 04:59 PM
OLSON LAURIE JExecutive Vice PresidentJun 06Sale36.4519,000692,58282,886Jun 08 01:11 PM
CORNWELL W DONDirectorJun 04Sale36.405,223190,1170Jun 05 04:44 PM
READ IAN CChairman & CEOMay 01Sale36.01132,3124,764,0811,144,703May 03 04:19 PM
JOHNSON RADY AExecutive Vice PresidentMar 13Sale36.5527,323998,66643,178Mar 14 05:19 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 13Sale36.8950,0001,844,39883,857Mar 14 05:13 PM
Dolsten MikaelPresident R&DMar 09Sale36.5969,6992,550,39451,185Mar 12 05:01 PM
HILL CHARLES HExecutive Vice PresidentMar 06Sale35.7642,3931,515,98557,328Mar 07 04:09 PM
Dolsten MikaelPresident R&DMar 02Sale35.8513,986501,398120,884Mar 05 09:23 AM
HILL CHARLES HExecutive Vice PresidentFeb 28Option Exercise27.37101,8722,788,237207,942Mar 02 03:24 PM
YOUNG JOHN DGroup PresidentFeb 28Option Exercise27.37121,1453,315,739362,707Mar 02 04:10 PM
OLSON LAURIE JExecutive Vice PresidentFeb 28Option Exercise27.3738,5461,055,004132,702Mar 02 04:02 PM
READ IAN CChairman & CEOFeb 28Option Exercise27.37649,78017,784,4791,774,184Mar 02 04:03 PM
SUSMAN SALLYExecutive Vice PresidentFeb 28Option Exercise27.37110,1323,014,313245,362Mar 02 04:03 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50239,801Mar 02 03:44 PM
JOHNSON RADY AExecutive Vice PresidentFeb 28Option Exercise27.3719,273527,50285,910Mar 02 03:44 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 28Option Exercise27.3746,8061,281,080171,276Mar 02 03:44 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 28Option Exercise27.37104,6262,863,614384,219Mar 02 03:44 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 28Option Exercise27.37209,2515,727,200655,161Mar 02 03:24 PM
BOURLA ALBERTChief Operating OfficerFeb 28Option Exercise27.3739,9231,092,693184,120Mar 02 03:24 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 28Option Exercise27.3733,040904,305136,847Mar 02 03:24 PM
Dolsten MikaelPresident R&DFeb 28Option Exercise27.37198,2385,425,774293,352Mar 02 03:24 PM
HILL CHARLES HExecutive Vice PresidentFeb 28Sale36.8326,779986,292181,163Mar 02 03:24 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27Sale37.0333,3681,235,591135,230Feb 28 06:14 PM
Dolsten MikaelPresident R&DFeb 27Sale37.0464,5872,392,31395,114Feb 28 06:04 PM
CORNWELL W DONDirectorFeb 27Sale37.0530011,1150Feb 28 01:29 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 26Sale37.199,510353,67717,770Feb 27 07:38 PM
CORNWELL W DONDirectorFeb 26Sale36.741,45853,5640Feb 28 01:29 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9043,520822,528223,733Feb 27 08:59 PM
READ IAN CChairman & CEOFeb 24Option Exercise19.83903,55917,917,2651,560,007Feb 27 08:58 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9015,716297,03290,222Feb 27 07:53 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456206,972Feb 27 07:51 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9015,885300,22762,848Feb 27 07:43 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9028,288534,643112,081Feb 27 07:43 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.9091,8761,736,456313,499Feb 27 07:43 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 24Option Exercise18.9015,957301,58736,959Feb 27 07:38 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 24Option Exercise18.9039,555747,590143,152Feb 27 07:38 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9065,2801,233,792122,609Feb 27 07:38 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90174,0813,290,131225,265Feb 27 07:32 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9028,288534,643116,769Feb 27 07:30 PM
BOURLA ALBERTChief Operating OfficerFeb 24Option Exercise18.9025,387479,814158,170Feb 27 07:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90174,0813,290,131511,470Feb 27 07:30 PM